Don Mattingly wins debut as Phillies interim manager as Jesús Luzardo helps blank Giants 7-0

PHILADELPHIA (AP) — Don Mattingly won his first game as Philadelphia's interim manager, as Jesús Luzardo threw seven innings to lead the last-place Phillies past the San Francisco Giants 7-0 on Tuesday night.

Mattingly won hours after he was promoted from bench coach to replace the fired Rob Thomson after the NL East champion Phillies lost 11 of 12 games and began the day tied for the worst record in the majors.

Dave Dombrowski, the Phillies’ president of baseball operations, flirted with the idea of replacing Thomson with former Red Sox manager Alex Cora. Cora was fired by Boston over the weekend but won a World Series with the team in 2018 when Dombrowski ran the front office.

Cora declined, citing family reasons. Dombrowski promoted Mattingly, the former New York Yankees great, who had two previous managerial stints with the Los Angeles Dodgers and Miami Marlins.

Mattingly — who officially works for his son, general manager Preston Mattingly — said ahead of the game he believed the Phillies had the talent needed to play to their potential and turn the season around.

For a night, at least, he was right.

Thomson, who led the Phillies to four straight playoff appearances, said before the game he was to be going to spend his unexpected free night watching the Phillies.

What he saw was more of what the Phillies expected out of Luzardo (2-3) this season.

He allowed two hits, struck out eight and walked none, just two starts after the lefty allowed nine runs and 12 hits against the Cubs. It was the third time in his first four starts Luzardo allowed five-plus earned runs.

Brandon Marsh hit a sacrifice fly in the fourth off Giants starter Tyler Mahle (1-4) and the Phillies tacked on four more runs in the sixth. Bryce Harper — who called Thomson perhaps the best manager he ever played for — hit an RBI double and Adolis Garcia ripped a two-RBI double to right-center in the inning.

Trea Turner had four hits.

Mahle gave up five runs in five innings.

The Giants send RHP Logan Webb (2-3, 4.86 ERA) to the mound against Phillies LHP Cristopher Sánchez (2-2, 2.94 ERA).

AP MLB: https://apnews.com/hub/MLB

Philadelphia Phillies' Brandon Marsh, right, follows through after hitting an RBI-sacrifice fly against San Francisco Giants pitcher Tyler Mahle during the fourth inning of a baseball game Tuesday, April 28, 2026, in Philadelphia. (AP Photo/Matt Slocum)

Philadelphia Phillies' Adolis García reacts after hitting a two-run double against San Francisco Giants pitcher Tyler Mahle during the sixth inning of a baseball game Tuesday, April 28, 2026, in Philadelphia. (AP Photo/Matt Slocum)

San Francisco Giants' Matt Gage pitches during the sixth inning of a baseball game against the Philadelphia Phillies Tuesday, April 28, 2026, in Philadelphia. (AP Photo/Matt Slocum)

Philadelphia Phillies' Alec Bohm hits a run-scoring double against San Francisco Giants pitcher Matt Gage during the sixth inning of a baseball game Tuesday, April 28, 2026, in Philadelphia. (AP Photo/Matt Slocum)

FILE - Philadelphia Phillies bench coach Don Mattingly (8) watches from the dugout steps during the sixth inning of a baseball game against the Colorado Rockies, April 5, 2026, in Denver. (AP Photo/David Zalubowski, File)

The U.S. Food and Drug Administration has approved a generic version of the world’s only twice-a-year shot to prevent HIV — a big step toward making the drug available inexpensively and more quickly in 120 low- and middle-income countries.

The announcement was made on Monday morning by the manufacturer and organizations that helped to speed up development of the medication, called lenacapavir.

The drug is expected to cost $40 a year per person in the countries where it will be available, the same price as daily preventive pills available now. But the shots are much more convenient than the pills because they’re needed much less frequently and they nearly eliminated new infections in two groundbreaking studies of people at high risk.

People don’t always take their daily dose of medication, “and if you do not take it, you cannot get protected against HIV,” said Carmen Pérez Casas, HIV lead for the grant-making organization Unitaid, a global health agency. “With lenacapavir, we are much more hopeful.”

Ultimately, advocates said, the medication should help drive down cases of HIV and AIDS — and deaths. According to the World Health Organization, 41 million people worldwide were living with HIV and 570,000 died from HIV-related causes last year.

With an affordable, high-quality generic medication now available, “we could help to scale this to the 20 million people around the world who need PrEP,” prescription medicine taken by people at risk of HIV before being exposed to the virus, said Carolyn Amole, who leads the HIV program for the Clinton Health Access Initiative, a global health organization.

“And if we scale to those levels,” she added, “we can actually begin to bring an end to the HIV epidemic.”

Generic lenacapavir can’t be sold in the U.S. because a brand-name version, Yeztugo, made by Gilead Sciences and approved last year, is still protected by a patent. The U.S. list price for that version, meaning the cost before insurance, is $28,218 a year. Gilead officials say that’s similar to some other types of PrEP, which stands for pre-exposure prophylaxis.

The new generic was approved by the FDA under a longstanding practice designed to ensure the quality of HIV-related drugs provided to other countries by the U.S. government. Approval of a drug by the U.S. FDA can speed regulatory approval in many other countries. The approval is considered “tentative,” the FDA's standard designation for generics while the originator remains under patent.

Until now, Gilead has been the sole supplier of lenacapavir, and demand has outstripped supply in low- and middle-income countries. Last year, Gilead established royalty-free licensing agreements with six generic manufacturers to enable production. Those voluntary licenses cover a specific set of countries in sub-Saharan Africa, Asia and Latin America.

“We share the sense of urgency around expanding access to lenacapavir for HIV prevention,” a Gilead spokesperson said in a statement. “We believe we have enabled the fastest and most sustainable path to expanding access for communities most affected by HIV.”

The generic was developed by India-based Dr. Reddy’s Laboratories under an agreement brokered by Unitaid, the Clinton Health Access Initiative and Wits RHI, a health research institute in Africa. The partners sought to accelerate development and make the drug available at an affordable price.

Common side effects with lenacapavir include injection site reactions, headache and nausea. People also must be tested for HIV prior to starting the drug and with each injection; drug-resistant HIV has been identified when used by people with an undiagnosed HIV infection.

“For any kind of PrEP … you need to have HIV testing in advance,” said Saiqa Mullick, director of implementation science with Wits RHI. “For many of the low- and middle-income countries, that is a rapid test.”

Generic lenacapavir should start to become available in some places within weeks, those helping with the effort said, although it could take a bit longer in countries that require the drug to go through their own approval processes before people can start taking it. Generic versions made by the other manufacturers have yet to be approved by FDA.

“The work is not done. Now, we need the funding to actually buy it for everyone who needs it and then we need to do the hard work of getting it to the millions of people who need it and want it,” Amole said. “But this is a great milestone.”

Casas said she’s optimistic that scientific advances — along with political will and funding — can help the world curb HIV.

“Now,” she said, “we have the tools.”

Gerald Imray in Cape Town, South Africa, contributed to this story.

The Associated Press’ health and science coverage receives financial support from the AP Fund for Journalism and private foundations. AP is solely responsible for all content. Find AP’s standards for working with philanthropies, a list of supporters and funded coverage areas at AP.org.

A nurse prepares a syringe before injecting a patient with the new HIV prevention drug lenacapavir at the ART clinic at Mbarara City Council Health Center IV in western Uganda, Aug. 21, 2026. (AP Photo/Hajarah Nalwadda)

FILE - The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, April 22, 2025. (AP Photo/Jose Luis Magana, File)